Status:
UNKNOWN
Superb Micro-vascular Imaging for Evaluation of Hepatic Lesions
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Conditions:
Hepatic Lesion
Eligibility:
All Genders
18-80 years
Brief Summary
Superb Micro-vascular Imaging (SMI) based on the iBeam platform is used to evaluate the blood supply of solid tumors. Compared with color Doppler technology, the sensitivity, accuracy and consistency ...
Detailed Description
To evaluate the diagnostic accuracy of SMI (primary outcome) when applying on the hepatic lesion. Each US findings during exam for patients with hepatic lesion were recorded by radiologist. Sample s...
Eligibility Criteria
Inclusion
- Visible hepatic lesion on US
- Agree to participate in the study
- Accessible follow-up imaging or pathological results
Exclusion
- 1\. Pregnant women
Key Trial Info
Start Date :
April 18 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04917354
Start Date
April 18 2017
End Date
April 1 2024
Last Update
June 8 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The second affilliated hospital of Zhejiang University school of medicine
Hangzhou, Zhejiang, China